PharmaCyte Biotech Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 218/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
PharmaCyte Biotech Inc's Score
Industry at a Glance
Industry Ranking
218 / 404
Overall Ranking
410 / 4562
Industry
Biotechnology & Medical Research
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
0.000
Target Price
0.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
PharmaCyte Biotech Inc Highlights
StrengthsRisks
PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is -0.69, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 457.38K shares, decreasing 56.94% quarter-over-quarter.
PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
Ticker SymbolPMCB
CompanyPharmaCyte Biotech Inc
CEOSilverman (Joshua N)
Websitehttps://pharmacyte.com/
FAQs
What is the current price of PharmaCyte Biotech Inc (PMCB)?
The current price of PharmaCyte Biotech Inc (PMCB) is 0.765.
What is the symbol of PharmaCyte Biotech Inc?
The ticker symbol of PharmaCyte Biotech Inc is PMCB.
What is the 52-week high of PharmaCyte Biotech Inc?
The 52-week high of PharmaCyte Biotech Inc is 1.900.
What is the 52-week low of PharmaCyte Biotech Inc?
The 52-week low of PharmaCyte Biotech Inc is 0.630.
What is the market capitalization of PharmaCyte Biotech Inc?
The market capitalization of PharmaCyte Biotech Inc is 5.20M.
What is the net income of PharmaCyte Biotech Inc?
The net income of PharmaCyte Biotech Inc is 23.36M.
Is PharmaCyte Biotech Inc (PMCB) currently rated as Buy, Hold, or Sell?
According to analysts, PharmaCyte Biotech Inc (PMCB) has an overall rating of --, with a price target of --.
What is the Earnings Per Share (EPS TTM) of PharmaCyte Biotech Inc (PMCB)?
The Earnings Per Share (EPS TTM) of PharmaCyte Biotech Inc (PMCB) is -1.116.